TScan Therapeutics, Inc. (NASDAQ:TCRX) Insider Sells $951,885.08 in Stock

TScan Therapeutics, Inc. (NASDAQ:TCRX) insider Zoran Zdraveski sold 164,686 shares of TScan Therapeutics stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $5.78, for a total transaction of $951,885.08. Following the completion of the sale, the insider now owns 4,716 shares of the company’s stock, valued at approximately $27,258.48. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

TScan Therapeutics Price Performance

Shares of NASDAQ:TCRX opened at $5.64 on Friday. TScan Therapeutics, Inc. has a 1-year low of $2.14 and a 1-year high of $9.69. The company has a current ratio of 7.77, a quick ratio of 7.77 and a debt-to-equity ratio of 0.08. The stock’s fifty day simple moving average is $6.30 and its two-hundred day simple moving average is $7.17. The stock has a market cap of $298.75 million, a PE ratio of -4.41 and a beta of 0.83.

TScan Therapeutics (NASDAQ:TCRX) last posted its earnings results on Monday, August 12th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.02. The firm had revenue of $0.54 million for the quarter, compared to analysts’ expectations of $1.55 million. TScan Therapeutics had a negative net margin of 855.84% and a negative return on equity of 59.83%. As a group, analysts forecast that TScan Therapeutics, Inc. will post -1.17 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have weighed in on TCRX shares. Wedbush reaffirmed an “outperform” rating and issued a $10.00 price target on shares of TScan Therapeutics in a research note on Monday, August 12th. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of TScan Therapeutics in a research report on Tuesday, August 13th. Needham & Company LLC reiterated a “buy” rating and issued a $11.00 price target on shares of TScan Therapeutics in a report on Monday, August 12th. Finally, BTIG Research assumed coverage on TScan Therapeutics in a report on Thursday, May 16th. They set a “buy” rating and a $12.00 price objective for the company. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $12.00.

Institutional Investors Weigh In On TScan Therapeutics

Several large investors have recently made changes to their positions in TCRX. Vanguard Group Inc. grew its position in TScan Therapeutics by 1.1% during the first quarter. Vanguard Group Inc. now owns 1,808,152 shares of the company’s stock valued at $14,357,000 after buying an additional 20,000 shares during the period. Great Point Partners LLC bought a new stake in shares of TScan Therapeutics in the 2nd quarter worth approximately $5,504,000. Marshall Wace LLP lifted its stake in TScan Therapeutics by 60.8% in the second quarter. Marshall Wace LLP now owns 307,487 shares of the company’s stock valued at $1,799,000 after purchasing an additional 116,316 shares during the last quarter. Tocqueville Asset Management L.P. bought a new position in TScan Therapeutics during the first quarter valued at $1,685,000. Finally, abrdn plc purchased a new stake in TScan Therapeutics in the fourth quarter worth $1,166,000. 82.83% of the stock is owned by hedge funds and other institutional investors.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.